Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Eton Pharmaceuticals (ETON) over the last 2 years, with Sep 2025 value amounting to -$284,000.

  • Eton Pharmaceuticals' Cash from Investing Activities was N/A to -$284,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.1 million, marking a year-over-year change of. This contributed to the annual value of -$40.0 million for FY2024, which is 5063.10% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Cash from Investing Activities is -$284,000, which was up 99.26% from -$38.1 million recorded in Q4 2024.
  • In the past 5 years, Eton Pharmaceuticals' Cash from Investing Activities ranged from a high of -$2,000 in Q3 2021 and a low of -$38.1 million during Q4 2024.
  • Its 3-year average for Cash from Investing Activities is -$10.3 million, with a median of -$1.3 million in 2023.
  • Examining YoY changes over the last 5 years, Eton Pharmaceuticals' Cash from Investing Activities showed a top increase of 99.63% in 2022 and a maximum decrease of 99,900.00% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$3.3 million in 2021, then soared by 99.63% to -$12,000 in 2022, then slumped by 6,358.33% to -$775,000 in 2023, then plummeted by 4,820.26% to -$38.1 million in 2024, then reached -$284,000 in 2025.
  • Its Cash from Investing Activities was -$284,000 in Q3 2025, compared to -$38.1 million in Q4 2024 and -$1.9 million in Q1 2024.